DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 74 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactEarnings

Chandan Healthcare Limited — Outcome of Board Meeting

NSE 1 hr ago·7 Sept 2026, 11:11 am

Chandan Healthcare

Chandan Healthcare Limited has informed the stock exchange that its board of directors held a meeting on September 7, 2026. The company has released the outcome of this meeting, though specific details regarding agenda items or decisions have not been disclosed in the public notice.

This update is a routine corporate disclosure that signals the board's regular oversight of the company's affairs. For investors, it confirms that the company is adhering to standard governance protocols. While the lack of specific details means there are no immediate market-moving announcements, the board's continued engagement is a positive sign of operational activity.

Investors should monitor the company's future filings for any further details on the meeting's outcomes. Until more information is available, the stock's performance will likely remain driven by broader market trends and the company's quarterly results.